|
2023
|
Invention
|
Aav-mediated expression of long-acting anti-ccr5 binding agents for the treatment and prevention ... |
|
|
Invention
|
Long-acting anti-ccr5 binding agents for the prevention and treatment of hiv.
The present disclo... |
|
|
P/S
|
Therapeutic preparations, namely, therapeutic preparations for the treatment of HIV, cancer, graf... |
|
|
Invention
|
Methods of treating nafld and nash. The present disclosure provides CCR5 binding agents that are ... |
|
2021
|
Invention
|
Methods of treating coronavirus infection. e.g., e.g., coronavirus infection) using a CCR5 bindin... |
|
|
Invention
|
Ccr5 binding agent for treatment of ccr5 positive metastatic cancer. The present disclosure relat... |
|
|
Invention
|
Ccr5 binding agent for the treatment of ccr5 positive metastatic cancer.
The present disclosure ... |
|
2020
|
Invention
|
Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor age... |
|
|
Invention
|
Anti-ccr5 agents and methods of treatment that block cancer metastasis or enhance cell death indu... |
|
|
Invention
|
Substitution monotherapy treatment for hiv-1 infection employing antibody pro140.
This invention... |
|
2019
|
Invention
|
Methods for reducing viral load in hiv-1 infected patients.
This invention provides a method of ... |
|
2018
|
Invention
|
Screening methods for identifying and treating hiv-1 infected patient sub-populations suitable fo... |
|
|
Invention
|
Methods for treating or preventing graft-versus-host disease involving the administration of anti... |
|
|
Invention
|
Humanized mouse model.
The present invention provides for inhibition or blockade of immunomodula... |
|
|
Invention
|
Humanized mouse model. The present invention provides for inhibition or blockade of immunomodulat... |
|
|
Invention
|
Concentrated protein formulations and uses thereof. Described are low viscosity, hypotonic formul... |
|
2016
|
Invention
|
Inhibition of ccl5 ligand binding to ccr5 receptor and alteration of ccr5/ccl5 axis signaling in ... |
|
2015
|
Invention
|
Substitution monotherapy treatment for hiv-1 infection employing antibody pro140. This invention ... |
|
|
Invention
|
Hiv antibody therapy as treatment substitute. This invention relates to the use of antibody thera... |
|
|
Invention
|
Use of anti-ccr5 antibodies in graft versus host disease.
This composition and method provides f... |
|
|
Invention
|
Use of anti-ccr5 antibodies in graft versus host disease. This composition and method provides fo... |
|
2014
|
Invention
|
Methods for inhibiting hiv-1 replication involving the administration of an anti-ccr5 receptor mo... |
|
|
Invention
|
Felinized antibodies and methods of treating retroviral infections in felines. Provided are felin... |
|
2012
|
Invention
|
Methods for reducing viral load in hiv-1 infected patients. 10 at about nine days following admin... |
|
|
Invention
|
Anti-cd11a antibodies and uses thereof.
Provided herein are isolated human, chimeric, and humani... |
|
|
Invention
|
Anti-cd11a antibodies and uses thereof. Provided herein are isolated human, chimeric, and humaniz... |
|
|
Invention
|
Methods of treating retroviral infections in felines.
Provided are methods for treating or reduc... |
|
|
Invention
|
Methods of treating retroviral infections in felines. Provided are methods for treating or reduci... |
|
2011
|
Invention
|
Method for preventing hiv-1 infection of cd4+ cells.
This invention provides methods for inhibit... |
|
2008
|
Invention
|
Methods of inhibiting infection by diverse subtypes of drug-resistant hiv-1.
This invention prov... |
|
2007
|
Invention
|
Ccr5 chemokine receptor-specific monoclonal antibodies capable of inhibiting hiv-1 cell fusion. +... |
|
1999
|
Invention
|
Methods of inhibiting human immunodeficiency virus type 1 (hiv-1) infection through the administr... |
